Loxo Oncology (LOXO) Releases LOXO-101 Data; Oppenheimer Raises Price Target to $30

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. GOOGL
5. APGE
6. MU
7. DFTX
8. LLY
9. RGNX
10. LCO

Go back to Loxo Oncology (LOXO) Releases LOXO-101 Data; Oppenheimer Raises Price Target to $30

Loxo Oncology TRK Inhibitor LOXO-101 Demonstrates Promising Clinical Activity and Safety in Phase 1 Trial

November 8, 2015 10:30 AM EST

Six Patients with TRK Fusion Cancers Enrolled; All Remain on Study

Three Patients with TRK Fusion Cancers Evaluable for Efficacy and All Show Objective Responses

Company to Host Investor Conference Call and Webcast to Review the Data on Monday, November 9, 2015 at 8:00 a.m. EST

STAMFORD, Conn., Nov. 08, 2015 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq: LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced new results from its Phase 1 open-label, dose-escalation trial of LOXO-101, a... More

Loxo Oncology Announces Transition of Chief Medical Officer

November 5, 2015 6:45 AM EST

STAMFORD, Conn., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq: LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that Jennifer Low, M.D., Ph.D., chief medical officer and executive vice president, R&D, has decided to transition from her current role with Loxo Oncology. Over the next several months, Dr. Low will remain at Loxo Oncology as acting chief medical officer, as an employee through the end of 2015 and in an advisory role thereafter.

I would like to thank... More